Identification of trans-RV metabolite gradients in PAH reveals impaired β-oxidation and lipotoxicity, offering novel biomarkers and therapeutic targets.
In PAH, trans-RV and transpulmonary metabolite gradients exist and correlate with haemodynamic determinants of clinical outcome. The most pronounced differential trans-RV gradients are known to be involved in lipid metabolism/lipotoxicity, that is, accumulation of long chain FAs. The identified accumulation of dicarboxylic acids and acylcarnitines likely indicates impaired β-oxidation in the hypertensive RV and represents emerging biomarkers and therapeutic targets in PAH.
Chouvarine et al. (Thu,) studied this question.